Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Virtual examination of human lungs on a modern interface screen

Early Detection of Treatment Response in Lung Cancer Using Delta-Radiomics Features

The study conducted by Heidelberg University Hospital investigates the use of diffusion-weighted MRI (DWI) to predict early treatment outcomes in…

The image serves as a graphical abstract, displaying visuals from the study, ranging from MRI scans to the analysis of delta-radiomics texture features

Heidelberg University Hospital: Delta-Radiomics Features from ADC Maps as Early Predictors of Treatment Success in Lung Cancer Therapy

In this prospective study conducted by Heidelberg University Hospital, researchers investigated whether changes in radiomic features from…

Puzzle pieces connecting to an interoperable system

Healthcare on FHIR: Igniting the Potential of Interoperability

Interoperability plays a crucial role in healthcare: it enables seamless communication of patient information across different systems, leads to…